Hybrigenics Launches Pharma Industry’s First Proteomics Database For Hiv Drug Development Proprietary Hiv Bioinformatics Platform At Keystone Symposia MeetingMarch 29, 2001Paris, France - Hybrigenics, the functional proteomics company, announces the launch of the world’s most comprehensive combined protein-protein interactions “map” between the human immunodeficiency virus (HIV) and its host cell in humans. This represents the first time that a fully integrated HIV-Human protein pathway has been described; it is an invaluable tool to identify new drug targets against AIDS. The protein database known as PIMRider® HIV(1), will be launched today during a poster presentation at the Keystone Symposia HIV Pathogenesis meeting (Keystone, Colorado, USA), one of the world’s leading molecular and cellular biology research showcases. Hybrigenics’ proprietary database will enable researchers for the first time to assign functions to proteins involved in interactions between the HIV virus and its human host cells, or lymphocytes. Combined analysis of these interactions allows deductions on the implication of various basic lymphocyte actions in the HIV replication cycle, as well as concerted actions of several viral proteins with the same cellular machinery. The identification of protein pathways is a key step to validating drug targets against HIV and developing therapeutics for treatment of HIV infections. Based on its proprietary bioinformatics platform, Hybrigenics has compiled and integrated all the protein interaction information known and available in the scientific literature about the HIV to generate a powerful database resource. PIMRider® HIV includes published data concerning 132 interactions between all proteins contained in HIV-type 1 and 87 human cellular proteins, as well as useful bibliographic links to the human genome, HIV databases, description of sequences and structure of proteins. This is the first time that HIV-lymphocyte protein interactions have been documented in a single database which allows researchers also to benefit from sophisticated visualization tools for insights into protein pathways, and provides the basis for therapeutic target validation. The resulting Protein Interaction Map (PIM®) includes the display of several functional pathways, and can be used to gather comprehensive biological annotations on interacting HIV and lymphocytes proteins. “The launch of this unique database marks a major advance in the development of novel research strategies, and in the translation of HIV viral genomic data, into potentially useful vaccines and other therapeutics,” said Dr. Donny Strosberg, CEO of Hybrigenics. “We are confident that the unique ‘user-friendly’ visual presentation of this data – depicting a global picture of the virus and its protein-based relations with human host cells -- and the free subscription for our partners in the academic community worldwide, will help accelerate this important pursuit.” W3C (World Wide Web Consortium) |
|||||||||||||||||||||
| Related HIV Current Events and HIV News Articles Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." AIDS research reveals a lack of family-planning programs in Uganda University of Alberta graduate student Jennifer Heys wants to make her message clear: there needs to be more education in Ugandan communities about contraception. Many pregnant women avoid HIV screening in Africa 'Prevention is the best cure' is a common expression, but what happens if preventative measures are not used? A large proportion of pregnant Ugandan women are going out of their way not to be HIV tested, increasing the risk of mother-to-child transmission. An atomic-level look at an HIV accomplice Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity. New findings suggest strategy to help generate HIV-neutralizing antibodies New discoveries about anti-HIV antibodies may bring researchers a step closer to creating an effective HIV vaccine, according to a new paper co-authored by scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria A rapid and accurate diagnosis is the first step towards treatment in the fight against infectious disease. No-entry zones for AIDS virus The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs. Hoping for a fluorescent basket case Although recent advances have raised hopes that a protective vaccine can be developed, acquired immunodeficiency syndrome (AIDS) remains a major public health problem. Scientists explain binding action of 2 key HIV antibodies; could lead to new vaccine design A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. More HIV Current Events and HIV News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||